NetCann is a top quality cannabis innovator: a company that not only produces and commercializes cannabis, but goes the extra mile utilizing the whole value chain.
That is why we are the leading integrated company in Latin America's cannabis industry.

NetCann combines leading-edge efficient technologies with the best human value and outstanding technical assets. We are deeply committed to the development of local communities, gender equity and environmental sustainability

We were the first company to complete the whole cannabis value chain, with a modern pharmaceutical infrastructure and the necessary quality certifications, including the valuable GAP and GMP Certificates.

Our agro-industrial infrastructure of more than 90 acres of cultivation, coupled with more than 85,000 ft² greenhouses, an 80-ton pharmaceutical drying plant and an in-house world-class CBD extraction and purification laboratory, makes us stand out and validates NetCann as the leading experts in the field.




ft² greenhouses

pharmaceutical drying plant



Extraction plant



Business verticals

NetCann has both B2B and B2C business lines reflecting its positioning in the entire value chain all this encompassed with a high quality, pharmaceutical grade production:

Active pharmaceutical ingredients (APIs)

Active pharmaceutical ingredients (APIs)

Dried flowers

Dried flowers

Medical / pharmaceutical final products

Medical / pharmaceutical products

Final consumer / wellness products

consumer and wellness products

Our products

Wellness and consumption
B2B and B2C product lines

Raw Material (API)

+ 99% pure Pharma Grade
and GMP

Medical Products

CBD 5%

CBD 10%

THC 2.7% - CBD 2.5% (in stability)

THC 0.9% - CBD 2% (in stability)

Cosmetic Products


ERB CBD Hand and body cream

ERB CBD Liquid hand soap


Other products

R + D for new formulations according to customer demand

White Labels ready for sale

Medical Cannabis: a growing industry

The medical cannabis sector is revolutionizing the farmaceutical market on a global scale, not only because of its preventive and mitigating use, but for the research, development and job opening opportunities it provides.

We are the first Latin-American cannabis company to have a commercial partnership with Megalabs, a leading pharmaceutical conglomerate present in 18 countries of the region.

Uruguay is at the forefront of medical cannabis production in the world.

Its interest in technology and innovation at the service of health and wellness, position it as an avant-garde country for the generation of new businesses. Building on the experience of Uruguay's groundbreaking legislation, NetCann has become the only Latin-American cannabis company with a presence in all business verticals of the cannabis industry: non-psychoactive CBD-based medical and wellness cannabis, and psychoactive THC-based medical and wellness cannabis.


Bússola & Cia: QuiteJá projeta recuperar R$ 1 bilhão em 2023

A Associação Brasileira das Indústrias de Canabinoides (BRCann) realizou levantamento junto à Anvisa (Agência Nacional de Vigilância Sanitária) que mostrou aumento de 492% nas autorizações de importação de produtos de cannabis para uso médico em 2021. A NetCann quer trazer seus produtos para o Brasil, se associando a laboratórios nacionais. E já busca o registro na Anvisa para iniciar suas ações no país.

Read more

Canabidiol: uruguaia desembarca no Brasil para explorar uso medicinal

Indústria legal da erva deve atingir os US$ 57 milhões até 2027

O uso da cannabis está cada dia mais em pauta na comunidade científica, na imprensa e nos grupos que defendem a importância de seu uso medicinal. Neste sentido, governos de todo o mundo já estudam suas aplicações e, segundo dados da Forbes, a indústria legal vai atingir os US$ 57 milhões em 2027. Desse valor, 33% devem ser destinados ao uso para a saúde pública.

Read more

NetCann quer explorar uso medicinal da cannabis no Brasil

Indústria legal da erva deve atingir os US$ 57 milhões até 2027

Já faz tempo em que a cannabis deixou de ser vista pela área médica como algo prejudicial. Segundo dados da Forbes, a indústria legal atingirá os US$ 57 milhões em 2027. Desse valor, 33% devem ser destinados ao uso para a saúde pública.

Read more